Advances in molecular mechanisms of inflammatory bowel disease‑associated colorectal cancer (Review)
- Authors:
- Zhi Wang
- Yu Chang
- Haibo Sun
- Yuqin Li
- Tongyu Tang
-
Affiliations: Department of Gastroenterology, The First Hospital of Jilin University, Changchun, Jilin 130000, P.R. China - Published online on: April 9, 2024 https://doi.org/10.3892/ol.2024.14390
- Article Number: 257
-
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Medzhitov R: Origin and physiological roles of inflammation. Nature. 454:428–435. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C and Flavell RA: Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 13:759–771. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS and Pujari VB: Inflammation and cancer. Ann Afr Med. 18:121–126. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang YZ and Li YY: Inflammatory bowel disease: Pathogenesis. World J Gastroenterol. 20:91–99. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Choi WT, Yozu M, Miller GC, Shih AR, Kumarasinghe P, Misdraji J, Harpaz N and Lauwers GY: Nonconventional dysplasia in patients with inflammatory bowel disease and colorectal carcinoma: A multicenter clinicopathologic study. Mod Pathol. 33:933–943. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Nguyen ED, Wang D, Lauwers GY and Choi WT: Increased histologic inflammation is an independent risk factor for nonconventional dysplasia in ulcerative colitis. Histopathology. 81:644–652. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Lukas M: Inflammatory bowel disease as a risk factor for colorectal cancer. Dig Dis. 28:619–624. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Eaden JA, Abrams KR and Mayberry JF: The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut. 48:526–535. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Lutgens MWMD, van Oijen MGH, van der Heijden GJMG, Vleggaar FP, Siersema PD and Oldenburg B: Declining risk of colorectal cancer in inflammatory bowel disease: An updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 19:789–799. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu F, Xia Y, Parker AS and Verma IM: IKK biology. Immunol Rev. 246:239–253. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Karin M and Ben-Neriah Y: Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev Immunol. 18:621–663. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF and Karin M: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 118:285–296. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Koliaraki V, Pasparakis M and Kollias G: IKKβ in intestinal mesenchymal cells promotes initiation of colitis-associated cancer. J Exp Med. 212:2235–2251. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Schön S, Flierman I, Ofner A, Stahringer A, Holdt LM, Kolligs FT and Herbst A: β-catenin regulates NF-κB activity via TNFRSF19 in colorectal cancer cells. Int J Cancer. 135:1800–1811. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C and Mukaida N: Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 118:560–570. 2008.PubMed/NCBI | |
|
Hamilton KE, Simmons JG, Ding S, Van Landeghem L and Lund PK: Cytokine induction of tumor necrosis factor receptor 2 is mediated by STAT3 in colon cancer cells. Mol Cancer Res. 9:1718–1731. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Onizawa M, Nagaishi T, Kanai T, Nagano K, Oshima S, Nemoto Y, Yoshioka A, Totsuka T, Okamoto R, Nakamura T, et al: Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly involved in colitis-associated carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 296:G850–G859. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu Q, Man SM, Gurung P, Liu Z, Vogel P, Lamkanfi M and Kanneganti TD: Cutting edge: STING mediates protection against colorectal tumorigenesis by governing the magnitude of intestinal inflammation. J Immunol. 193:4779–4782. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bozec D, Iuga AC, Roda G, Dahan S and Yeretssian G: Critical function of the necroptosis adaptor RIPK3 in protecting from intestinal tumorigenesis. Oncotarget. 7:46384–46400. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fukata M, Hernandez Y, Conduah D, Cohen J, Chen A, Breglio K, Goo T, Hsu D, Xu R and Abreu MT: Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis. 15:997–1006. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, et al: Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 133:1869–1881. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Luo Q, Zeng L, Tang C, Zhang Z, Chen Y and Zeng C: TLR9 induces colitis-associated colorectal carcinogenesis by regulating NF-κB expression levels. Oncol Lett. 20:1102020. View Article : Google Scholar : PubMed/NCBI | |
|
Girondel C, Lévesque K, Langlois MJ, Pasquin S, Saba-El-Leil MK, Rivard N, Friesel R, Servant MJ, Gauchat JF, Lesage S and Meloche S: Loss of interleukin-17 receptor D promotes chronic inflammation-associated tumorigenesis. Oncogene. 40:452–464. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Hardbower DM, Coburn LA, Asim M, Singh K, Sierra JC, Barry DP, Gobert AP, Piazuelo MB, Washington MK and Wilson KT: EGFR-mediated macrophage activation promotes colitis-associated tumorigenesis. Oncogene. 36:3807–3819. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Rizzo A, De Mare V, Rocchi C, Stolfi C, Colantoni A, Neurath MF, Macdonald TT, Pallone F, Monteleone G and Fantini MC: Smad7 induces plasticity in tumor-infiltrating Th17 cells and enables TNF-alpha-mediated killing of colorectal cancer cells. Carcinogenesis. 35:1536–1546. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bhat AA, Ahmad R, Uppada SB, Singh AB and Dhawan P: Claudin-1 promotes TNF-α-induced epithelial-mesenchymal transition and migration in colorectal adenocarcinoma cells. Exp Cell Res. 349:119–127. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kawai N, Tsuji S, Tsujii M, Ito T, Yasumaru M, Kakiuchi Y, Kimura A, Komori M, Sasaki Y, Hayashi N, et al: Tumor necrosis factor alpha stimulates invasion of Src-activated intestinal cells. Gastroenterology. 122:331–339. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N, et al: Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell. 23:634–646. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM and Yu H: Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell. 15:283–293. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Atreya R and Neurath MF: Signaling molecules: The pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr Drug Targets. 9:369–374. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitalla S, et al: gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell. 15:91–102. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Pathria P, Gotthardt D, Prchal-Murphy M, Putz EM, Holcmann M, Schlederer M, Grabner B, Crncec I, Svinka J, Musteanu M, et al: Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice. OncoImmunology. 4:e9985292015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Wang DH, Yang X, Sun Y and Yang CS: Colitis-induced IL11 promotes colon carcinogenesis. Carcinogenesis. 42:557–569. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Heichler C, Scheibe K, Schmied A, Geppert CI, Schmid B, Wirtz S, Thoma OM, Kramer V, Waldner MJ, Büttner C, et al: STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis. Gut. 69:1269–1282. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
He Z, He X, Chen Z, Ke J, He X, Yuan R, Cai Z, Chen X, Wu X and Lan P: Activation of the mTORC1 and STAT3 pathways promotes the malignant transformation of colitis in mice. Oncol Rep. 32:1873–1880. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, Sata M, Scheller J, Rose-John S, Kado S and Takada T: Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol. 184:1543–1551. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Rizzo A, Di Giovangiulio M, Stolfi C, Franzè E, Fehling HJ, Carsetti R, Giorda E, Colantoni A, Ortenzi A, Rugge M, et al: RORγt-expressing Tregs drive the growth of colitis-associated colorectal cancer by controlling IL6 in dendritic cells. Cancer Immunol Res. 6:1082–1092. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Putoczki TL, Thiem S, Loving A, Busuttil RA, Wilson NJ, Ziegler PK, Nguyen PM, Preaudet A, Farid R, Edwards KM, et al: Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell. 24:257–271. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L and Karin M: IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 15:103–113. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Stolfi C, Rizzo A, Franzè E, Rotondi A, Fantini MC, Sarra M, Caruso R, Monteleone I, Sileri P, Franceschilli L, et al: Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med. 208:2279–2290. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Nishina T, Deguchi Y, Ohshima D, Takeda W, Ohtsuka M, Shichino S, Ueha S, Yamazaki S, Kawauchi M, Nakamura E, et al: Interleukin-11-expressing fibroblasts have a unique gene signature correlated with poor prognosis of colorectal cancer. Nat Commun. 12:22812021. View Article : Google Scholar : PubMed/NCBI | |
|
Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, Hait NC, Allegood JC, Price MM, Avni D, et al: Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 23:107–120. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, Kortylewski M, Horne D, Somlo G, Forman S, et al: STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med. 16:1421–1428. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pillon-Thomas S, Niu G, Kay H, Mulé J, Kerr WG, et al: Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 11:1314–1321. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Park SB, Choi B, Lee BJ, Kim NJ, Jeong YA, Joo MK, Kim HJ, Park JJ, Kim JS, Noh YS and Lee HJ: Intestinal epithelial deletion of sphk1 prevents colitis-associated cancer development by inhibition of epithelial STAT3 activation. Dig Dis Sci. 65:2284–2293. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, et al: TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 21:491–501. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, Drake C, Pardoll D and Yu H: Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell. 15:114–123. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Olesch C, Sirait-Fischer E, Berkefeld M, Fink AF, Susen RM, Ritter B, Michels BE, Steinhilber D, Greten FR, Savai R, et al: S1PR4 ablation reduces tumor growth and improves chemotherapy via CD8+ T cell expansion. J Clin Invest. 130:5461–5476. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tewari D, Bawari S, Sharma S, DeLiberto LK and Bishayee A: Targeting the crosstalk between canonical Wnt/β-catenin and inflammatory signaling cascades: A novel strategy for cancer prevention and therapy. Pharmacol Ther. 227:1078762021. View Article : Google Scholar : PubMed/NCBI | |
|
White BD, Chien AJ and Dawson DW: Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology. 142:219–232. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Clevers H and Nusse R: Wnt/β-catenin signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bian J, Dannappel M, Wan C and Firestein R: Transcriptional regulation of Wnt/β-catenin pathway in colorectal cancer. Cells. 9:21252020. View Article : Google Scholar : PubMed/NCBI | |
|
Takayama T, Ohi M, Hayashi T, Miyanishi K, Nobuoka A, Nakajima T, Satoh T, Takimoto R, Kato J, Sakamaki S and Niitsu Y: Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology. 121:599–611. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, et al: The consensus molecular subtypes of colorectal cancer. Nat Med. 21:1350–1356. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Brown JB, Lee G, Managlia E, Grimm GR, Dirisina R, Goretsky T, Cheresh P, Blatner NR, Khazaie K, Yang GY, et al: Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology. 138:595–605, 605.e1-e3. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Claessen MMH, Schipper MEI, Oldenburg B, Siersema PD, Offerhaus GJA and Vleggaar FP: WNT-pathway activation in IBD-associated colorectal carcinogenesis: Potential biomarkers for colonic surveillance. Cell Oncol. 32:303–310. 2010.PubMed/NCBI | |
|
Chakrabarty S, Varghese VK, Sahu P, Jayaram P, Shivakumar BM, Pai CG and Satyamoorthy K: Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia. Br J Cancer. 117:136–143. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ma B and Hottiger MO: Crosstalk between Wnt/β-catenin and NF-κB signaling pathway during inflammation. Front Immunol. 7:3782016. View Article : Google Scholar : PubMed/NCBI | |
|
Rubinstein MR, Wang X, Liu W, Hao Y, Cai G and Han YW: Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 14:195–206. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wu S, Morin PJ, Maouyo D and Sears CL: Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. Gastroenterology. 124:392–400. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Iwakura Y and Ishigame H: The IL-23/IL-17 axis in inflammation. J Clin Invest. 116:1218–1222. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D and Yu H: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 206:1457–1464. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chen XW and Zhou SF: Inflammation, cytokines, the IL-17/IL-6/STAT3/NF-κB axis, and tumorigenesis. Drug Des Devel Ther. 9:2941–2946. 2015.PubMed/NCBI | |
|
Hyun YS, Han DS, Lee AR, Eun CS, Youn J and Kim HY: Role of IL-17A in the development of colitis-associated cancer. Carcinogenesis. 33:931–936. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA and Oft M: IL-23 promotes tumour incidence and growth. Nature. 442:461–465. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Popa C, Netea MG, van Riel PLCM, van der Meer JWM and Stalenhoef AFH: The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 48:751–762. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chen G and Goeddel DV: TNF-R1 signaling: A beautiful pathway. Science. 296:1634–1635. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Balkwill F: TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 25:409–416. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 431:461–466. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Seidelin JB and Nielsen OH: Continuous cytokine exposure of colonic epithelial cells induces DNA damage. Eur J Gastroenterol Hepatol. 17:363–369. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Porter RJ, Arends MJ, Churchhouse AMD and Din S: Inflammatory bowel disease-associated colorectal cancer: Translational risks from mechanisms to medicines. J Crohns Colitis. 15:2131–2141. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Huycke MM, Abrams V and Moore DR: Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. Carcinogenesis. 23:529–536. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Kay J, Thadhani E, Samson L and Engelward B: Inflammation-induced DNA damage, mutations and cancer. DNA Repair (Amst). 83:1026732019. View Article : Google Scholar : PubMed/NCBI | |
|
Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z and Podolsky DK: Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Gut. 36:718–723. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Meira LB, Bugni JM, Green SL, Lee CW, Pang B, Borenshtein D, Rickman BH, Rogers AB, Moroski-Erkul CA, McFaline JL, et al: DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest. 118:2516–2525. 2008.PubMed/NCBI | |
|
Rajamäki K, Taira A, Katainen R, Välimäki N, Kuosmanen A, Plaketti RM, Seppälä TT, Ahtiainen M, Wirta EV, Vartiainen E, et al: Genetic and epigenetic characteristics of inflammatory bowel disease-associated colorectal cancer. Gastroenterology. 161:592–607. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Burmer GC, Rabinovitch PS, Haggitt RC, Crispin DA, Brentnall TA, Kolli VR, Stevens AC and Rubin CE: Neoplastic progression in ulcerative colitis: Histology, DNA content, and loss of a p53 allele. Gastroenterology. 103:1602–1610. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Yaeger R, Shah MA, Miller VA, Kelsen JR, Wang K, Heins ZJ, Ross JS, He Y, Sanford E, Yantiss RK, et al: Genomic alterations observed in colitis-associated cancers are distinct from those found in sporadic colorectal cancers and vary by type of inflammatory bowel disease. Gastroenterology. 151:278–287.e6. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ and Harris CC: Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: A cancer-prone chronic inflammatory disease. Cancer Res. 60:3333–3337. 2000.PubMed/NCBI | |
|
Rabinovitch PS, Dziadon S, Brentnall TA, Emond MJ, Crispin DA, Haggitt RC and Bronner MP: Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res. 59:5148–5153. 1999.PubMed/NCBI | |
|
Redston MS, Papadopoulos N, Caldas C, Kinzler KW and Kern SE: Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology. 108:383–392. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Kraus S and Arber N: Inflammation and colorectal cancer. Curr Opin Pharmacol. 9:405–410. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E and Rodriguez Yoldi M: Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int J Mol Sci. 18:1972017. View Article : Google Scholar : PubMed/NCBI | |
|
Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR and Rabinovitch PS: DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology. 103:1611–1620. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Carethers JM: Screening for colorectal cancer in African Americans: Determinants and rationale for an earlier age to commence screening. Dig Dis Sci. 60:711–721. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Colotta F, Allavena P, Sica A, Garlanda C and Mantovani A: Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis. 30:1073–1081. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Fujiwara I, Yashiro M, Kubo N, Maeda K and Hirakawa K: Ulcerative colitis-associated colorectal cancer is frequently associated with the microsatellite instability pathway. Dis Colon Rectum. 51:1387–1394. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Din S, Wong K, Mueller MF, Oniscu A, Hewinson J, Black CJ, Miller ML, Jiménez-Sánchez A, Rabbie R, Rashid M, et al: Mutational analysis identifies therapeutic biomarkers in inflammatory bowel disease-associated colorectal cancers. Clin Cancer Res. 24:5133–5142. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sato F, Harpaz N, Shibata D, Xu Y, Yin J, Mori Y, Zou TT, Wang S, Desai K, Leytin A, et al: Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res. 62:1148–1151. 2002.PubMed/NCBI | |
|
Azarschab P, Porschen R, Gregor M, Blin N and Holzmann K: Epigenetic control of the E-cadherin gene (CDH1) by CpG methylation in colectomy samples of patients with ulcerative colitis. Genes Chromosomes Cancer. 35:121–126. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Kuester D, Guenther T, Biesold S, Hartmann A, Bataille F, Ruemmele P, Peters B, Meyer F, Schubert D, Bohr UR, et al: Aberrant methylation of DAPK in long-standing ulcerative colitis and ulcerative colitis-associated carcinoma. Pathol Res Pract. 206:616–624. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Vincan E and Barker N: The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis. 25:657–663. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kinchen J, Chen HH, Parikh K, Antanaviciute A, Jagielowicz M, Fawkner-Corbett D, Ashley N, Cubitt L, Mellado-Gomez E, Attar M, et al: Structural remodeling of the human colonic mesenchyme in inflammatory bowel disease. Cell. 175:372–386.e17. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lin WW and Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 117:1175–1183. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Thiesen S, Janciauskiene S, Uronen-Hansson H, Agace W, Högerkorp CM, Spee P, Håkansson K and Grip O: CD14(hi)HLA-DR(dim) macrophages, with a resemblance to classical blood monocytes, dominate inflamed mucosa in Crohn's disease. J Leukoc Biol. 95:531–541. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ruffell B, Affara NI and Coussens LM: Differential macrophage programming in the tumor microenvironment. Trends Immunol. 33:119–126. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gordon S: Alternative activation of macrophages. Nat Rev Immunol. 3:23–35. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, et al: A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood. 107:2112–2122. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Dinapoli MR, Calderon CL and Lopez DM: The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. J Exp Med. 183:1323–1329. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Li L, Xu C, Wang Y, Wang Z, Chen M, Jiang Z, Pan J, Yang C, Li X, et al: Cross-talk between the gut microbiota and monocyte-like macrophages mediates an inflammatory response to promote colitis-associated tumourigenesis. Gut. 70:1495–1506. 2020.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Sime W, Juhas M and Sjölander A: Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration. Eur J Cancer. 49:3320–3334. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Martinez FO, Sica A, Mantovani A and Locati M: Macrophage activation and polarization. Front Biosci. 13:453–461. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Maisonneuve C, Tsang DKL, Foerster EG, Robert LM, Mukherjee T, Prescott D, Tattoli I, Lemire P, Winer DA, Winer S, et al: Nod1 promotes colorectal carcinogenesis by regulating the immunosuppressive functions of tumor-infiltrating myeloid cells. Cell Rep. 34:1086772021. View Article : Google Scholar : PubMed/NCBI | |
|
Ibrahim ML, Klement JD, Lu C, Redd PS, Xiao W, Yang D, Browning DD, Savage NM, Buckhaults PJ, Morse HC III and Liu K: Myeloid-derived suppressor cells produce IL-10 to elicit DNMT3b-dependent IRF8 silencing to promote colitis-associated colon tumorigenesis. Cell Rep. 25:3036–3046.e6. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Suzuki E, Kapoor V, Jassar AS, Kaiser LR and Albelda SM: Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 11:6713–6721. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Bronte V, Serafini P, Apolloni E and Zanovello P: Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother. 24:431–446. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Katoh H, Wang D, Daikoku T, Sun H, Dey SK and Dubois RN: CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell. 24:631–644. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM and Chen SH: Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66:1123–1131. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sinha P, Clements VK, Bunt SK, Albelda SM and Ostrand-Rosenberg S: Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 179:977–983. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pagès F and Galon J: Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 71:1263–1271. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, Wang Z, Wang C, Zhang Z, Xia W, et al: γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity. 40:785–800. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sade-Feldman M, Kanterman J, Ish-Shalom E, Elnekave M, Horwitz E and Baniyash M: Tumor necrosis factor-α blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity. 38:541–554. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
He D, Li H, Yusuf N, Elmets CA, Li J, Mountz JD and Xu H: IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol. 184:2281–2288. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Ohkura N, Kitagawa Y and Sakaguchi S: Development and maintenance of regulatory T cells. Immunity. 38:414–423. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Z, Friedrich C, Hagemann SC, Korte WH, Goharani N, Cording S, Eberl G, Sparwasser T and Lochner M: Regulatory T cells promote a protective Th17-associated immune response to intestinal bacterial infection with C. rodentium. Mucosal Immunol. 7:1290–1301. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chang LY, Lin YC, Mahalingam J, Huang CT, Chen TW, Kang CW, Peng HM, Chu YY, Chiang JM, Dutta A, et al: Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res. 72:1092–1102. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kryczek I, Wu K, Zhao E, Wei S, Vatan L, Szeliga W, Huang E, Greenson J, Chang A, Roliński J, et al: IL-17+ regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol. 186:4388–4395. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Blatner NR, Mulcahy MF, Dennis KL, Scholtens D, Bentrem DJ, Phillips JD, Ham S, Sandall BP, Khan MW, Mahvi DM, et al: Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer. Sci Transl Med. 4:164ra1592012. View Article : Google Scholar : PubMed/NCBI | |
|
Olguín JE, Medina-Andrade I, Molina E, Vázquez A, Pacheco-Fernández T, Saavedra R, Pérez-Plasencia C, Chirino YI, Vaca-Paniagua F, Arias-Romero LE, et al: Early and partial reduction in CD4+Foxp3+ regulatory T cells during colitis-associated colon cancer induces CD4+ and CD8+ T cell activation inhibiting tumorigenesis. J Cancer. 9:239–249. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Koliaraki V, Roulis M and Kollias G: Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis. J Clin Invest. 122:4231–4242. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Neufert C, Becker C, Türeci Ö, Waldner MJ, Backert I, Floh K, Atreya I, Leppkes M, Jefremow A, Vieth M, et al: Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J Clin Invest. 123:1428–1443. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sasaki S, Baba T, Shinagawa K, Matsushima K and Mukaida N: Crucial involvement of the CCL3-CCR5 axis-mediated fibroblast accumulation in colitis-associated carcinogenesis in mice. Int J Cancer. 135:1297–1306. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kawamura T, Yamamoto M, Suzuki K, Suzuki Y, Kamishima M, Sakata M, Kurachi K, Setoh M, Konno H and Takeuchi H: Tenascin-C produced by intestinal myofibroblasts promotes colitis-associated cancer development through angiogenesis. Inflamm Bowel Dis. 25:732–741. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Fujita M, Ito-Fujita Y, Iyoda T, Sasada M, Okada Y, Ishibashi K, Osawa T, Kodama H, Fukai F and Suzuki H: Peptide TNIIIA2 Derived from tenascin-C contributes to malignant progression in colitis-associated colorectal cancer via β1-integrin activation in fibroblasts. Int J Mol Sci. 20:27522019. View Article : Google Scholar : PubMed/NCBI | |
|
Bai YP, Shang K, Chen H, Ding F, Wang Z, Liang C, Xu Y, Sun MH and Li YY: FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7. Cancer Sci. 106:1278–1287. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hamilton KE, Chatterji P, Lundsmith ET, Andres SF, Giroux V, Hicks PD, Noubissi FK, Spiegelman VS and Rustgi AK: Loss of stromal IMP1 promotes a tumorigenic microenvironment in the colon. Mol Cancer Res. 13:1478–1486. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ma X, Aoki T, Tsuruyama T and Narumiya S: Definition of prostaglandin E2-EP2 signals in the colon tumor microenvironment that amplify inflammation and tumor growth. Cancer Res. 75:2822–2832. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Natividad JMM and Verdu EF: Modulation of intestinal barrier by intestinal microbiota: Pathological and therapeutic implications. Pharmacol Res. 69:42–51. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Slack E, Hapfelmeier S, Stecher B, Velykoredko Y, Stoel M, Lawson MA, Geuking MB, Beutler B, Tedder TF, Hardt WD, et al: Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science. 325:617–620. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Nagao-Kitamoto H, Kitamoto S and Kamada N: Inflammatory bowel disease and carcinogenesis. Cancer Metastasis Rev. 41:301–316. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Fantini MC and Guadagni I: From inflammation to colitis-associated colorectal cancer in inflammatory bowel disease: Pathogenesis and impact of current therapies. Dig Liver Dis. 53:558–565. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
LeBlanc JG, Laiño JE, del Valle MJ, Vannini V, van Sinderen D, Taranto MP, de Valdez GF, de Giori GS and Sesma F: B-group vitamin production by lactic acid bacteria-current knowledge and potential applications. J Appl Microbiol. 111:1297–1309. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Quaglio AEV, Grillo TG, De Oliveira ECS, Stasi LCD and Sassaki LY: Gut microbiota, inflammatory bowel disease and colorectal cancer. World J Gastroenterol. 28:4053–4060. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Thursby E and Juge N: Introduction to the human gut microbiota. Biochem J. 474:1823–1836. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yan H and Ajuwon KM: Butyrate modifies intestinal barrier function in IPEC-J2 cells through a selective upregulation of tight junction proteins and activation of the Akt signaling pathway. PLoS One. 12:e01795862017. View Article : Google Scholar : PubMed/NCBI | |
|
Isobe J, Maeda S, Obata Y, Iizuka K, Nakamura Y, Fujimura Y, Kimizuka T, Hattori K, Kim YG, Morita T, et al: Commensal-bacteria-derived butyrate promotes the T-cell-independent IgA response in the colon. Int Immunol. 32:243–258. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gomaa EZ: Human gut microbiota/microbiome in health and diseases: A review. Antonie Van Leeuwenhoek. 113:2019–2040. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kinnebrew MA, Ubeda C, Zenewicz LA, Smith N, Flavell RA and Pamer EG: Bacterial flagellin stimulates Toll-like receptor 5-dependent defense against vancomycin-resistant Enterococcus infection. J Infect Dis. 201:534–543. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T, et al: Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 504:446–450. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang M, Zhou Q, Dorfman RG, Huang X, Fan T, Zhang H, Zhang J and Yu C: Butyrate inhibits interleukin-17 and generates Tregs to ameliorate colorectal colitis in rats. BMC Gastroenterol. 16:842016. View Article : Google Scholar : PubMed/NCBI | |
|
Zimmerman MA, Singh N, Martin PM, Thangaraju M, Ganapathy V, Waller JL, Shi H, Robertson KD, Munn DH and Liu K: Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am J Physiol Gastrointest Liver Physiol. 302:G1405–G1415. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Janeway CA Jr: Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol. 54:1–13. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Kawai T and Akira S: Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 34:637–650. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Cario E and Podolsky DK: Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 68:7010–7017. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Fukata M, Shang L, Santaolalla R, Sotolongo J, Pastorini C, España C, Ungaro R, Harpaz N, Cooper HS, Elson G, et al: Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis. 17:1464–1473. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Frantz AL, Rogier EW, Weber CR, Shen L, Cohen DA, Fenton LA, Bruno ME and Kaetzel CS: Targeted deletion of MyD88 in intestinal epithelial cells results in compromised antibacterial immunity associated with downregulation of polymeric immunoglobulin receptor, mucin-2, and antibacterial peptides. Mucosal Immunol. 5:501–512. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmed I, Roy BC, Khan SA, Septer S and Umar S: Microbiome, metabolome and inflammatory bowel disease. Microorganisms. 4:202016. View Article : Google Scholar : PubMed/NCBI | |
|
Parekh PJ, Balart LA and Johnson DA: The influence of the gut microbiome on obesity, metabolic syndrome and gastrointestinal disease. Clin Transl Gastroenterol. 6:e912015. View Article : Google Scholar : PubMed/NCBI | |
|
Ghouri YA, Tahan V and Shen B: Secondary causes of inflammatory bowel diseases. World J Gastroenterol. 26:3998–4017. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Richard ML, Liguori G, Lamas B, Brandi G, da Costa G, Hoffmann TW, Pierluigi Di Simone M, Calabrese C, Poggioli G, Langella P, et al: Mucosa-associated microbiota dysbiosis in colitis associated cancer. Gut Microbes. 9:131–142. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Muller M, Hansmannel F, Arnone D, Choukour M, Ndiaye NC, Kokten T, Houlgatte R and Peyrin-Biroulet L: Genomic and molecular alterations in human inflammatory bowel disease-associated colorectal cancer. United European Gastroenterol J. 8:675–684. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Pan HW, Du LT, Li W, Yang YM, Zhang Y and Wang CX: Biodiversity and richness shifts of mucosa-associated gut microbiota with progression of colorectal cancer. Res Microbiol. 171:107–114. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Proença MA, Biselli JM, Succi M, Severino FE, Berardinelli GN, Caetano A, Reis RM, Hughes DJ and Silva AE: Relationship between Fusobacterium nucleatum, inflammatory mediators and microRNAs in colorectal carcinogenesis. World J Gastroenterol. 24:5351–5365. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tahara T, Hirata I, Nakano N, Tahara S, Horiguchi N, Kawamura T, Okubo M, Ishizuka T, Yamada H, Yoshida D, et al: Potential link between Fusobacterium enrichment and DNA methylation accumulation in the inflammatory colonic mucosa in ulcerative colitis. Oncotarget. 8:61917–61926. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Geis AL, Fan H, Wu X, Wu S, Huso DL, Wolfe JL, Sears CL, Pardoll DM and Housseau F: Regulatory T-cell response to enterotoxigenic Bacteroides fragilis colonization triggers IL17-dependent colon carcinogenesis. Cancer Discov. 5:1098–1109. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wick EC, Rabizadeh S, Albesiano E, Wu X, Wu S, Chan J, Rhee KJ, Ortega G, Huso DL, Pardoll D, et al: Stat3 activation in murine colitis induced by enterotoxigenic Bacteroides fragilis. Inflamm Bowel Dis. 20:821–834. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Purcell RV, Permain J and Keenan JI: Enterotoxigenic Bacteroides fragilis activates IL-8 expression through Stat3 in colorectal cancer cells. Gut Pathog. 14:162022. View Article : Google Scholar : PubMed/NCBI | |
|
Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, Huso DL, Brancati FL, Wick E, McAllister F, et al: A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 15:1016–1022. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB, et al: Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 338:120–123. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
de Almeida CV, Taddei A and Amedei A: The controversial role of Enterococcus faecalis in colorectal cancer. Therap Adv Gastroenterol. 11:17562848187836062018. View Article : Google Scholar : PubMed/NCBI | |
|
Cao Y, Oh J, Xue M, Huh WJ, Wang J, Gonzalez-Hernandez JA, Rice TA, Martin AL, Song D, Crawford JM, et al: Commensal microbiota from patients with inflammatory bowel disease produce genotoxic metabolites. Science. 378:eabm32332022. View Article : Google Scholar : PubMed/NCBI | |
|
Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ and Watanabe T: Colorectal cancer. Nat Rev Dis Primers. 1:150652015. View Article : Google Scholar : PubMed/NCBI | |
|
Vallée A, Lecarpentier Y and Vallée JN: Targeting the canonical WNT/β-catenin pathway in cancer treatment using non-steroidal anti-inflammatory drugs. Cells. 8:7262019. View Article : Google Scholar : PubMed/NCBI | |
|
Dihlmann S and von Knebel Doeberitz M: Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer. 113:515–524. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Dihlmann S, Siermann A and von Knebel Doeberitz M: The nonsteroidal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene. 20:645–653. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, Peppelenbosch MP and Richel DJ: Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 68:1213–1220. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sonu I, Lin MV, Blonski W and Lichtenstein GR: Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease. Gastroenterol Clin North Am. 39:559–599. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Graham PM, Li JZ, Dou X, Zhu H, Misra HP, Jia Z and Li Y: Protection against peroxynitrite-induced DNA damage by mesalamine: Implications for anti-inflammation and anti-cancer activity. Mol Cell Biochem. 378:291–298. 2013. View Article : Google Scholar : PubMed/NCBI |
